Blue Cross NC Tocilizumab Coverage Update

Coverage and Medical Necessity Criteria

inv-01: Initial Therapy Criteria

Covered when ALL of the following are met (criteria vary by indication as detailed below):

General requirements: 1) Prescribed for an FDA‑approved indication listed in policy; 2) Prescriber is a specialist in the area of the patient's diagnosis or has consulted one; 3) Will not be used in combination with another biologic immunomodulator agent or Otezla; 4) No FDA‑labeled contraindications to the requested tocilizumab product; 5) Patient has been tested for latent tuberculosis when required by the prescribing information and treatment begun if positive; 6) Requested quantity does not exceed the maximum units allowed for the duration of approval; 7) Site‑of‑care criteria apply for inpatient or outpatient hospital administration.

See indication‑specific nodes below for age, required prior trials, and documentation expectations.

Rheumatoid Arthritis (RA) initial criteria: Patient has moderately to severely active RA AND is ≥18 years of age AND ONE of: (a) inadequate response to maximally tolerated methotrexate for ≥3 months; OR (b) inadequate response to another conventional agent used for RA for ≥3 months; OR (c) intolerance or hypersensitivity to a conventional agent; OR (d) FDA‑labeled contraindication to all listed conventional agents; OR (e) patient is currently established on an FDA‑approved biologic/systemic immunomodulator for RA with documented clinical benefit plus additional documentation if switching from preferred agents is requested.

Medical record documentation required for prior trials, intolerance/contraindication, or clinical benefit (see policy).

Giant Cell Arteritis (GCA) initial criteria: Diagnosis of GCA AND age ≥18 years AND ONE of: inadequate response to systemic corticosteroids for 7–10 days; OR intolerance/hypersensitivity to systemic corticosteroids; OR FDA‑labeled contraindication to all systemic corticosteroids; OR currently established on an FDA‑approved biologic/systemic immunomodulator for GCA with documented clinical benefit.

Medical record documentation required.

Polyarticular Juvenile Idiopathic Arthritis (PJIA) initial criteria: Diagnosis of moderately to severely active PJIA AND age ≥2 years AND ONE of: inadequate response to one conventional agent used for PJIA for ≥3 months; OR intolerance/hypersensitivity to one conventional agent; OR FDA‑labeled contraindication to all conventional agents; OR currently established on an FDA‑approved biologic/systemic immunomodulator for PJIA with documented clinical benefit.

Medical record documentation required.

Systemic Juvenile Idiopathic Arthritis (SJIA) initial criteria: Diagnosis of active SJIA AND age ≥2 years AND ONE of: inadequate response to at least one NSAID for ≥1 month; OR intolerance/hypersensitivity to NSAIDs; OR FDA‑labeled contraindication to all NSAIDs; OR inadequate response to another conventional agent for ≥3 months; OR intolerance/hypersensitivity to conventional agent; OR FDA‑labeled contraindication to all conventional agents; OR currently established on an FDA‑approved biologic/systemic immunomodulator for SJIA with documented clinical benefit.

Medical record documentation required.

Cytokine Release Syndrome (CRS) initial criteria: Diagnosis of severe or life‑threatening CRS AND age ≥2 years AND request is for intravenous administration AND patient has received or will receive CAR T cell therapy AND ONE of: CRS was induced by CAR T cell therapy OR agent prescribed proactively to be on‑hand prior to CAR T cell therapy.

Documentation of CAR T cell therapy and whether CRS is present or the agent is being prescribed proactively is required.

Systemic sclerosis‑associated interstitial lung disease (SSc‑ILD) initial criteria: Diagnosis of SSc‑ILD AND age ≥18 years AND ALL of: disease onset (first non‑Raynaud symptom) ≤5 years; presence of elevated laboratory inflammatory markers (e.g., CRP, ESR, platelet count); active disease defined by at least one specified clinical metric (e.g., mRSS change, new body area involvement, tendon friction rub); ILD confirmed by chest high‑resolution CT; other known causes of ILD excluded; AND ONE of: inadequate response to one immunosuppressant therapy; OR intolerance/hypersensitivity to one immunosuppressant therapy; OR FDA‑labeled contraindication to all immunosuppressant therapy; OR currently established on a biologic/systemic immunomodulator with documented clinical benefit.

Specific active‑disease definitions and required HRCT confirmation are specified in the policy; medical record documentation required.

Non‑preferred product (Actemra or non‑preferred biosimilar) initial criteria: If request is for Actemra or a non‑preferred tocilizumab biosimilar, ONE of: (a) trial and inadequate response to preferred biosimilar Tyenne (tocilizumab‑aazg); OR (b) intolerance, FDA‑labeled contraindication, or hypersensitivity to Tyenne that is not expected to occur with the requested agent; OR (c) documented serious adverse event to Tyenne requiring medical intervention that is not anticipated with the requested agent (prescriber must submit FDA MedWatch Adverse Event Reporting Form).

Medical record documentation and FDA MedWatch submission (when applicable) required.

inv-02: Continuation Therapy

Continuation therapy covered when criteria below are met:

Continuation eligibility: Patient was approved through Blue Cross NC initial criteria OR the patient would have met initial criteria at the time therapy was started; for SSc‑ILD additional specific continuation allowances apply per policy; otherwise continuation follows initial criteria.

Medical record documentation required to demonstrate prior approval or that initial criteria would have been met.

Clinical benefit for continuation: Patient has demonstrated positive clinical response while using the medication — e.g., improvement or maintained annual rate of decline in pulmonary function (FVC% predicted) for SSc‑ILD or other indication‑specific evidence of benefit.

Documentation of clinical response required in the medical record.

Biosimilar step therapy for continuation: Requests for Actemra or a non‑preferred tocilizumab biosimilar at continuation require ONE of: trial and inadequate response to preferred biosimilar Tyenne; OR intolerance/hypersensitivity/FDA‑labeled contraindication to Tyenne not expected with requested agent; OR documented serious adverse event to Tyenne with FDA MedWatch submission — same requirements as for initial therapy.

inv-03: Continuation Criteria / Dosing by Indication

Continuation criteria and dosing by indication per FDA label and product‑specific details

CRS (patients ≥2 years) IV dosing: IV dosing: weight <30 kg — 12 mg/kg per infusion; weight ≥30 kg — 8 mg/kg per infusion; dosing interval at least 8 hours between consecutive doses; not to exceed 800 mg per infusion; maximum of up to 4 doses.max 4 doses

Maximum units for CRS listed as 3,200 in product tables; proactive (on‑hand) prescribing prior to CAR T cell therapy is allowed per July 2026 update.

Rheumatoid Arthritis (adult) SC/IV dosing: SC and IV dosing per FDA label: SC examples — 162 mg schedules (weight‑based frequency: <100 kg every 2 weeks up to once weekly based on response; ≥100 kg once weekly); IV examples — 4–8 mg/kg every 4 weeks based on response, not to exceed 800 mg per infusion.see product‑specific maximum units

Different biosimilars have assigned HCPCS codes (see coding).

Giant Cell Arteritis (adult) dosing:

inv-03: Continuation Criteria / Dosing by Indication

Site of Care Medical Necessity Criteria

Inpatient administration: Injection or infusion may be given in an inpatient setting if above medical necessity criteria are met AND the inpatient admission is NOT for the sole purpose of administering the injection or infusion.

Outpatient hospital administration: Injection or infusion may be given in an outpatient hospital setting if above medical necessity criteria are met AND ONE of: history of a severe adverse event to the medication (e.g., anaphylaxis, seizure, thromboembolism, MI, renal failure); OR conditions that increase risk for severe adverse event (e.g., unstable renal or cardiopulmonary disease, unstable vascular access); OR history of mild adverse events not managed by pre‑medication; OR inability to adhere to treatment schedule; OR new to therapy (initial injection/infusion or <3 months since start); OR re‑initiation of therapy per defined gaps; OR requirement to change product formulation.

ref':'b0_5

title':'inv-05: Site of Care Criteria' } ]}],

inv-04: Quantity Limit Exceptions

Quantity Limit Exception Criteria

Titration allowance: Quantity requested may be approved for documented titration at initiation of therapy (authorization for up to a 90‑day titration period).

Dose strength substitution: Requested quantity must be necessary because the prescribed dose cannot be achieved using a lesser quantity of a higher strength formulation.

ref':'b0_4

title':'inv-04: Quantity Limit Exceptions'

note

The requested tocilizumab product must not be used in combination with another biologic immunomodulator agent or apremilast (Otezla®). This combination prohibition applies to all initial and continuation requests and medical record documentation must support the absence of concomitant biologic or Otezla use.

An inpatient admission that is solely for the purpose of administering the injection or infusion is not supported. Inpatient administration is allowable only when the medical necessity criteria are met and the admission is not for the sole purpose of drug administration; otherwise the Site of Care criteria require administration in an alternate setting (home infusion or physician office) or meeting one of the outpatient hospital exceptions.

Requests that exceed the policy's maximum units allowed for the duration of approval or that do not meet Site of Care requirements for inpatient or outpatient hospital administration may be considered not medically necessary. Quantity Limit Exception rules apply and require documentation when a dose exceeds standard limits (see exception criteria).

Requests that exceed labeled dosing without required prescriber documentation may be denied. If the requested quantity exceeds the maximum FDA‑labeled dose or the safest studied dose, the prescriber must submit supporting documentation (medical records or fax form) showing prior use, duration, and prior medication trials/failures. Additionally, requests for inpatient administration that are solely for infusion or injection may be considered not medically necessary under the Site of Care criteria.

Billing and Coding References

Referenced HCPCS codes for ActemraHCPCS

J3262

tocilizumab (Actemra) HCPCS (referenced)

Referenced HCPCS codes for biosimilarsHCPCS

Q5156

tocilizumab-anoh (Avtozma) HCPCS

Referenced HCPCS codes for biosimilars (additional context)HCPCS

Q5135	tocilizumab-aazg (Tyenne) HCPCS
Q5133	tocilizumab-bavi (Tofidence) HCPCS

HCPCS and historical billing codesHCPCS

Q5156	HCPCS for Avtozma (tocilizumab-anoh) IV/SC
Q5133	HCPCS for Tofidence (tocilizumab-bavi) IV
Q5135	HCPCS for Tyenne (tocilizumab-aazg) IV/SC
C9399	Deleted/termed miscellaneous code historically used for Tyenne (deleted 9/30/2024/2025)
J3490	Deleted/termed miscellaneous code historically used for Tyenne (deleted 9/30/2024/2025)
J3590	Deleted/termed miscellaneous code historically used for Tyenne (deleted 9/30/2024/2025)

Age thresholds by indication

Rheumatoid arthritis (RA)Age ≥18 years

Giant cell arteritis (GCA)Age ≥18 years

Systemic sclerosis-associated ILD (SSc-ILD)Age ≥18 years

Polyarticular juvenile idiopathic arthritis (PJIA)Age ≥2 years

Systemic juvenile idiopathic arthritis (SJIA)Age ≥2 years

Cytokine release syndrome (CRS) — IV onlyAge ≥2 years

Provider Requirements, Authorization, and Documentation

Prior Authorization

Prior Authorization and Coding References

Prior authorization required for tocilizumab products and biosimilars administered by a healthcare professional. See HCPCS coding and maximum units in the FDA label reference tables for each product; requests that do not meet medical necessity criteria may be denied.

Prior authorization required for Actemra (tocilizumab), Avtozma (tocilizumab-anoh), Tofidence (tocilizumab-bavi), and Tyenne (tocilizumab-aazg).
Refer to product-specific HCPCS listed in the FDA label reference tables (e.g., Q5135, Q5156, Q5133) for billing.

Documentation Required

Quantity Over Labeled Maximum

If the requested quantity (dose) exceeds the FDA labeled maximum or the safest studied dose per the manufacturer's product insert, the prescriber must submit supporting documentation demonstrating medical necessity for the higher dose. Documentation may include medical records or a completed fax form showing duration of use at the higher dose and prior medication trials/ failures.

Clinical Background and Context

Tocilizumab is an interleukin‑6 (IL‑6) receptor antagonist with multiple FDA‑approved indications including adult rheumatoid arthritis, giant cell arteritis, juvenile idiopathic arthritis (systemic and polyarticular forms), CAR T cell therapy–associated cytokine release syndrome (CRS), and systemic sclerosis‑associated interstitial lung disease (SSc‑ILD). Both intravenous and subcutaneous formulations are addressed by this policy, and indication‑specific dosing, age thresholds, and administration route requirements (for example, IV only for CRS) are specified in the coverage criteria.

Definitions and Condition Summaries

CRS (Cytokine Release Syndrome)

DefinitionSevere or life‑threatening inflammatory syndrome often associated with CAR T cell therapy

Indication and formulationCRS is an FDA‑recognized indication for IV tocilizumab (patients ≥2 years)

Policy implicationIV tocilizumab may be approved proactively to have on‑hand prior to CAR‑T therapy for treatment of CRS

SSc-ILD (Systemic sclerosis-associated interstitial lung disease)

DefinitionInterstitial lung disease associated with systemic sclerosis (SSc‑ILD)

Key approval criteriaDisease onset ≤5 years; elevated inflammatory markers (eg, CRP, ESR, platelet count); active disease per policy‑defined metrics; ILD confirmed by chest HRCT; exclusion of other causes

OpenPayer

Tocilizumab (Actemra) and Tocilizumab Biosimilars coverage

Coverage and Medical Necessity Criteria

Billing and Coding References

Provider Requirements, Authorization, and Documentation

Clinical Background and Context

Definitions and Condition Summaries